Akums - CDMO Leader serving the Indian Pharma space

AI Analysis

The CDMO segment in India is growing, driven by outsourcing trends and domestic pharma expansion. Akums' strong position and domestic focus make it resilient to global tariff risks.

Trading Insight

Long Akums Drugs and Pharmaceuticals, given its leadership in the Indian CDMO space and robust operational footprint.

Quick check: SUNPHARMA neutral (+0.3% 1d), CIPLA bearish bias (oversold).

Key Evidence

•Akums Drugs and Pharmaceuticals Ltd. is the largest CDMO focused on the Indian pharmaceutical market.
•Operations span more than 60 dosage forms.
•11 manufacturing plants and three R&D centres.
•Over 970 DCGI approvals and 200 first-to-market launches.
•Servicing a wide array of dosage formats for multinational and domestic clients.

Sectors:pharma

AI-powered analysis by

Anadi Algo News